Here, our immunohistochemical approach may help identify HGSOC cases that are associated with p53 aggregates, and these cases had a worse prognosis compared with other p53 aberrant cases, which suggested that classification of p53-mutated cancers including HGSOC that is based on p53 staining patterns may be useful for distinguishing p53 aggregate-positive cases, and thereby predicting chemoresistance. The gene discussed is TP53; the disease is cancer.